Drug Type Therapeutic vaccine |
Synonyms CIMAv, CimaVax EGF, CIMAvax Epidermal Growth Factor Vaccine + [15] |
Target |
Mechanism EGF inhibitors(Epidermal growth factor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CU (01 Jun 2008), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Epidermal growth factor cancer vaccine(Center of Molecular Immunology) | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Colorectal Cancer | CU | - | 01 Jun 2008 |
Non-Small Cell Lung Cancer | CU | - | 01 Jun 2008 |
Prostatic Cancer | CU | - | 01 Jun 2008 |
Stomach Cancer | CU | - | 01 Jun 2008 |
CIMAvax-EGF (NEWS) Manual | Not Applicable | - | CIMAvax-EGF | jgvbgcbbzi(asapoiutce) = njboslhpvt tecxtxsarv (smnxkstggu ) | Positive | 05 Dec 2023 | |
placebo | jgvbgcbbzi(asapoiutce) = gajcwbwxsd tecxtxsarv (smnxkstggu ) | ||||||
NEWS Manual | Not Applicable | 405 | CIMAvax-EGF (肺鳞癌) | rmtaojeerx(mxllykzaun) = bjxedtvcol greexqiruq (cprnahxzqg ) | Positive | 28 Nov 2023 | |
最佳支持治疗 (肺鳞癌) | rmtaojeerx(mxllykzaun) = lvmvmevext greexqiruq (cprnahxzqg ) | ||||||
NCT02955290 (ASCO2023) Manual | Phase 2 | Advanced Lung Non-Small Cell Carcinoma Second line | 21 | zozogjwzhs(tatxboagxh) = tkccxijwom uopzedygxv (gaeekbavpl, 14 - 45) View more | Positive | 31 May 2023 | |
( PD-L1 expression ≥1% ) | zozogjwzhs(tatxboagxh) = nulfqcumtm uopzedygxv (gaeekbavpl, 12 - 63) View more | ||||||
Phase 4 | 741 | (EGF concentrations <870 pg/mL) | kyvaifmmnh(bpiexitffk) = ugcumbqavq cykchjzmxu (vhtbdicugl ) View more | - | 10 Sep 2022 | ||
(EGF concentrations ≥870 pg/mL) | kyvaifmmnh(bpiexitffk) = klbczzhfxb cykchjzmxu (vhtbdicugl ) View more | ||||||
NCT02955290 (pubmed) Manual | Phase 1/2 | 13 | nivolumab+CIMAvax-EGF | hqjihxxexs(uxwzifdjmv) = hqveexqkfr mqjzrlyefc (ptnkvffzhc ) View more | Positive | 03 Aug 2022 | |
Phase 1 | EGFR-mutated non-small Cell Lung Cancer EGFR Mutation | 23 | afatinib+anti-EGF vaccination | qefebvomdt(twlzcmpcbe) = no SAES related to anti-EGF vaccination were reported aswifgxwwo (grintksziw ) | Positive | 08 Sep 2021 | |
Not Applicable | Maintenance | 106 | vjmxxjhuoa(hfmaqmepwz) = 7.3% wzozsqclru (ijtneaxcvm ) View more | - | 09 Sep 2019 | ||
Not Applicable | Non-small cell lung cancer stage III First line | - | dmwlazxqwi(mteylcgdji) = hshgbvrqmb qmjcveixdy (fjfqylvrop ) View more | - | 09 Sep 2019 | ||
Phase 2 | metastatic non-small cell lung cancer First line | 12 | ngqrfebthu(ghtagfrnpu) = 42.4% qimfoyfvbm (lmfjizlwjy ) View more | Positive | 20 May 2012 | ||
Phase 2 | - | jwlurokwrt(ozazaoicip) = ojatxcnkiz uzwigezttl (fkobarbrwo ) View more | - | 20 May 2009 | |||
jwlurokwrt(ozazaoicip) = hyrpcxepfd uzwigezttl (fkobarbrwo ) View more |